INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Price analytics
Returns
1 day
6.3%
1 week
0.0%
1 month
-8.1%
3 months
-28.4%
6 months
-52.1%
1 year
-57.5%
3 years
-71.7%
Risk
Volatility (1y ann.)
85.2%
Beta vs ASX 200
0.72
Sharpe (1y)
-0.58
VaR 95% (1-day)
-6.5%
Max drawdown (1y)
-70.6%
Off 1-year high
-68.8%
Technicals
RSI(14)
50
vs 50DMA
-6.5%
vs 200DMA
-43.3%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value69.6
Trailing P/E
—
Forward P/E
67
PEG ratio
—
EV / EBITDA
100
Price / Book
94
Price / Sales
0
Growth42.0
Revenue growth (1y)
0
Revenue CAGR (3y)
84
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum4.2
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
18
Position in 52-week range
2
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).